In FGFR3-mutant bladder cancer, concurrent RAS-MAPK activation is associated with a 2.1-fold higher recurrence risk and shorter time to resistance to erdafitinib (3.5 months vs. 5.6 months in wild-type) (11). This evidence concerns the gene FGFR3 and urinary bladder cancer.